Key result
Moderate-dose prednisolone is linked to myocarditis improvement in ~67% of systemic sclerosis patients.
Why the study?
Myocarditis occurs in systemic sclerosis, but treatment options and cardiac outcomes remain limited.
Does moderate-dose steroid therapy improve myocarditis in patients with systemic sclerosis?
Does moderate-dose steroid therapy improve myocarditis in patients with systemic sclerosis?
Moderate-dose steroid therapy may improve myocarditis in systemic sclerosis, though mortality remains high in patients with elevated biomarkers and impaired LVEF.
May support steroids for SSc myocarditis; hypothesis-generating observational data requiring RCTs before practice change.
Background. Myocarditis is reported in systemic sclerosis (SSc); however, treatment options and outcomes are limited. Our objective was to define cardiac outcomes after moderate-dose steroid therapy in SSc patients with myocarditis. Method. An open-label study was conducted among SSc patients with myocarditis—as defined by cardiovascular magnetic resonance (CMR), disease onset <5 years, and a NYHA functional class ≥II. All enrolled patients received prednisolone (30 mg/d) which would be tapered off by week 24, and CMR was followed up at the end of treatment. Results. A total of 20 SSc patients were enrolled which 12 patients completed the study. At week 24, 8 of the 12 cases experienced improvement of myocarditis. Compared to those with no improvement, these 8 patients had significantly longer disease duration ( <a:math xmlns:a="http://www.w3.org/1998/Math/MathML" id="M1"> <a:mi>p</a:mi> <a:mo>=</a:mo> <a:mn>0.03</a:mn> </a:math> ), higher heart rate at baseline ( <c:math xmlns:c="http://www.w3.org/1998/Math/MathML" id="M2"> <c:mi>p</c:mi> <c:mo>=</c:mo> <c:mn>0.049</c:mn> </c:math> ) and week 24 ( <e:math xmlns:e="http://www.w3.org/1998/Math/MathML" id="M3"> <e:mi>p</e:mi> <e:mo>=</e:mo> <e:mn>0.04</e:mn> </e:math> ), lower left ventricular (LV) and right ventricular (RV) stroke volume at baseline ( <g:math xmlns:g="http://www.w3.org/1998/Math/MathML" id="M4"> <g:mi>p</g:mi> <g:mo>=</g:mo> <g:mn>0.002</g:mn> </g:math> and <i:math xmlns:i="http://www.w3.org/1998/Math/MathML" id="M5"> <i:mi>p</i:mi> <i:mo>=</i:mo> <i:mn>0.01</i:mn> </i:math> ) and week 24 ( <k:math xmlns:k="http://www.w3.org/1998/Math/MathML" id="M6"> <k:mi>p</k:mi> <k:mo>=</k:mo> <k:mn>0.01</k:mn> </k:math> and <m:math xmlns:m="http://www.w3.org/1998/Math/MathML" id="M7"> <m:mi>p</m:mi> <m:mo>=</m:mo> <m:mn>0.02</m:mn> </m:math> ), and lower LV and RV cardiac output at week 24 ( <o:math xmlns:o="http://www.w3.org/1998/Math/MathML" id="M8"> <o:mi>p</o:mi> <o:mo>=</o:mo> <o:mn>0.01</o:mn> </o:math> and <q:math xmlns:q="http://www.w3.org/1998/Math/MathML" id="M9"> <q:mi>p</q:mi> <q:mo>=</q:mo> <q:mn>0.01</q:mn> </q:math> ). Four cases died during follow-up (3 due to cardiac complications, 1 due to renal crisis). The two who died from heart failure had very high NT-prohormone-brain natriuretic peptide (NT-proBNP) and impaired LV ejection fraction (LVEF), and the one who died from arrhythmia had very high sensitivity of cardiac Troponin-T (hs-cTnT). Conclusions. Moderate-dose steroid therapy may improve myocarditis in SSc. A proportion of patients died due to cardiac complications during treatment, particularly those with high hs-cTnT, high NT-proBNP, and impaired LVEF. This trial is registered with NCT03607071.
No takes yet. Share an insight, caveat, or question.
Pussadhamma et al. (2020) studied Systemic sclerosis with myocarditis (n=20). Prednisolone was evaluated on Improvement of myocarditis at week 24. Moderate-dose steroid therapy with prednisolone resulted in improvement of myocarditis in 8 of 12 (66.7%) systemic sclerosis patients who completed 24 weeks of treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: